---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020454"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:20:13.856315+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics reports Q1 2024 net loss $25.0M; cash $206.7M, runway into H1 2026

## Summary
- Net loss $25.0M vs $30.5M YoY; collaboration revenue $5.1M, flat vs prior year.
- Cash $206.7M as of Mar 31, 2024; expected cash runway into first half of 2026.
- FHD-286 combo in AML dose escalation ongoing; initial clinical data expected H2 2024.
- IND submitted for FHD-909 (first-in-class oral BRM selective inhibitor); Phase 1 in BRG1-mutated NSCLC expected H2 2024.
- Appointed Kristian Humer as CFO in April 2024.

## SEC filing metadata
- accession: 0001628280-24-020454
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/0001628280-24-020454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/fhtx-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020454
- JSON: https://secwatch.observer/filing/0001628280-24-020454.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020454.txt

## Key facts
- Earnings Releases
  Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 6, 2024, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828024020454/0001628280-24-020454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.